ImmuCell Q4 preliminary sales dip

Reuters

Jan 09

ImmuCell Q4 preliminary sales dip

Overview

Animal health company's preliminary Q4 sales declined 1.6% yr/yr
Domestic sales rose 8.7%, while international sales fell 52.6%

Outlook

Company focuses on expanding First Defense capacity after pausing Re-Tain investment
ImmuCell plans manufacturing improvements to support First Defense growth targets

Result Drivers

TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst
INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst
STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Product Sales		$7.60 mln

Press Release: ID:nGNX2gDkM2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602180163"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602180163\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602180163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602180163","market":"nz","top_or_hot":-1,"title":"ImmuCell Q4 preliminary sales dip","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ImmuCell Q4 preliminary sales dip</title></head><body><p><span>Overview</span></p><ul><li><p>Animal health company's preliminary Q4 sales declined 1.6% yr/yr</p></li><li><p>Domestic sales rose 8.7%, while international sales fell 52.6%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company focuses on expanding First Defense capacity after pausing Re-Tain investment</p></li><li><p>ImmuCell plans manufacturing improvements to support First Defense growth targets</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst</p></li><li><p>INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst</p></li><li><p>STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Sales</p></td><td></td><td><p>$7.60 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2gDkM2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuCell Q4 preliminary sales dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuCell Q4 preliminary sales dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 05:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ImmuCell Q4 preliminary sales dip</title></head><body><p><span>Overview</span></p><ul><li><p>Animal health company's preliminary Q4 sales declined 1.6% yr/yr</p></li><li><p>Domestic sales rose 8.7%, while international sales fell 52.6%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company focuses on expanding First Defense capacity after pausing Re-Tain investment</p></li><li><p>ImmuCell plans manufacturing improvements to support First Defense growth targets</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst</p></li><li><p>INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst</p></li><li><p>STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Sales</p></td><td></td><td><p>$7.60 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2gDkM2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCC","symbol_name":"伊芙美尔医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL1N3Y912S:1","article_id":"2602180163","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602180163","pubTimestamp":1767907647,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuCell Q4 preliminary sales dipOverviewAnimal health company's preliminary Q4 sales declined 1.6% yr/yrDomestic sales rose 8.7%, while international sales fell 52.6%OutlookCompany focuses on expandi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCC":"伊芙美尔医疗","BK4139":"生物科技"},"translate_title":"ImmuCell第四季度初步销售额下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCC":0.9},"content_text":"ImmuCell Q4 preliminary sales dipOverviewAnimal health company's preliminary Q4 sales declined 1.6% yr/yrDomestic sales rose 8.7%, while international sales fell 52.6%OutlookCompany focuses on expanding First Defense capacity after pausing Re-Tain investmentImmuCell plans manufacturing improvements to support First Defense growth targetsResult DriversTRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te BoekhorstINTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te BoekhorstSTRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-downKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Product Sales$7.60 mlnPress Release: ID:nGNX2gDkM2For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}